Subscribe To
Acceptance of polyamine inhibitor car-t combination abstract for online publication
MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...
October 25, 2023, 12:15 pm
panbela to host third quarter 2023 earnings conference call on november 9, 2023
MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...
October 24, 2023, 12:15 pm
panbela to host third quarter 2023 earnings conference call on november 9, 2023
MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical...
October 24, 2023, 8:15 am
panbela to present at h.c. wainwright 25th annual global investment conference
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-s...
August 28, 2023, 8:15 am
panbela announces issuance of new patent in europe for claims of a novel process for the production of sbp-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) — ...
August 14, 2023, 12:15 pm
panbela therapeutics, inc. (pbla) q2 2023 earnings call transcript
panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET C...
August 10, 2023, 10:42 pm
panbela opens enrollment in uk and germany for aspire trial in pancreatic cancer, all countries/regions in the aspire trial are now open and actively enrolling
Interim Data Analysis anticipated in Early 2024 MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) — panbela...
July 24, 2023, 12:15 pm
panbela announces issuance of new patent in australia patent is for claims of a novel process for the production of sbp-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) — ...
July 15, 2023, 6:59 am
panbela (pbla) up 11% on update from pancreatic cancer study
panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data f...
July 11, 2023, 2:02 pm
panbela announces poster presentation at the endocrine society meeting: polyamine inhibition and β-cell preservation in recent onset type 1 diabetes
MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...
June 26, 2023, 12:15 pm
panbela announces sponsored research agreement to evaluate polyamine metabolic inhibitor therapy in combination with car-t cell therapy
MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical ...
June 13, 2023, 12:15 pm
panbela announces poster presentation at immunology of diabetes society meeting: evaluating the potential of cpp-1x (eflornithine) in recent onset type 1 diabetes
MINNEAPOLIS, June 01, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical s...
June 1, 2023, 12:15 pm
panbela announces clinical trial with moffitt cancer center for phase i/ii program in stk11 mutant non-small cell lung cancer
MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical st...
May 22, 2023, 12:15 pm
panbela therapeutics, inc. (pbla) q1 2023 earnings call transcript
panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Compa...
May 7, 2023, 7:42 am
panbela provides business update and reports q1 2023 financial results
MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical st...
May 4, 2023, 8:10 pm
panbela to host first quarter 2023 earnings conference call on may 4, 2023
MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical ...
April 24, 2023, 8:15 am
panbela (pbla) enrolls first patient for type 1 diabetes drug
panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1...
April 13, 2023, 2:26 pm
panbela therapeutics, inc. (pbla) q4 2022 earnings call transcript
panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Co...
March 16, 2023, 7:49 pm
panbela announces pricing of approximately $15 million public offering
MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) — panbela Therapeutics, Inc. (Nasdaq: PBLA), (“...
January 26, 2023, 1:41 pm
panbela therapeutics, inc. (pbla) q3 2022 earnings calltranscripts
panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET...
November 13, 2022, 7:41 pm